MedPath
Found 3 clinical trials|View Analysis
Sort by:

Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

Phase 2
Recruiting
Conditions
Non-Resectable Pancreas Carcinoma
Interventions
Drug: Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection
First Posted Date
2024-05-01
Last Posted Date
2024-05-01
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
37
Registration Number
NCT06393166
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Evaluation of the High Intensity Focused Ultrasound (HIFU) Technique for Patients With Unresectable Pancreatic Tumor Treatment (PULS)

Phase 1
Recruiting
Conditions
Non-Resectable Pancreas Carcinoma
Interventions
Procedure: HIFU intervention
First Posted Date
2024-01-18
Last Posted Date
2024-07-17
Lead Sponsor
Centre Leon Berard
Target Recruit Count
26
Registration Number
NCT06211933
Locations
🇫🇷

CHU Estaing, Clermont-Ferrand, Auvergne Rhone-Alpes, France

🇫🇷

Centre Léon Bérard, Lyon, Rhone-alpes, France

Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients With Non-resectable Pancreatic Cancer

Phase 2
Recruiting
Conditions
Pancreas Cancer
Non-Resectable Pancreas Carcinoma
Interventions
First Posted Date
2023-05-03
Last Posted Date
2023-07-27
Lead Sponsor
Morten Ladekarl
Target Recruit Count
98
Registration Number
NCT05841420
Locations
🇩🇰

Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

© Copyright 2025. All Rights Reserved by MedPath